United Therapeutics Files 8-K for Undisclosed Event

TL;DR

**United Therapeutics filed an 8-K on Feb 27, 2024, for an unspecified "Other Event" from Feb 26, 2024; details are missing.**

AI Summary

United Therapeutics Corporation filed an 8-K on February 27, 2024, reporting an "Other Event" that occurred on February 26, 2024. The filing, identified by accession number 0001104659-24-027791, does not detail the specific nature of this event in the provided text.

Why It Matters

The significance of this 8-K filing for United Therapeutics Corporation cannot be assessed without the specific details of the "Other Event" reported on February 26, 2024.

Risk Assessment

Risk Level: medium — The filing reports an "Other Event" but provides no specific details, preventing any assessment of potential risks or opportunities.

Key Players & Entities

• United Therapeutics Corporation (company) — filer
• February 26, 2024 (date) — date of earliest event reported
• February 27, 2024 (date) — filing date
• 0001104659-24-027791 (identifier) — accession number

FAQ

Key Financial Figures

• $0.01 — h registered Common Stock, par value $0.01 per share UTHR Nasdaq Global Select

Filing Documents

• tm247282d1_8k.htm (8-K) — 28KB
• 0001104659-24-027791.txt ( ) — 196KB
• uthr-20240226.xsd (EX-101.SCH) — 3KB
• uthr-20240226_lab.xml (EX-101.LAB) — 33KB
• uthr-20240226_pre.xml (EX-101.PRE) — 22KB
• tm247282d1_8k_htm.xml (XML) — 3KB

01

Item 8.01. Other Events. On February 26, 2024, United Therapeutics Corporation (the Company ) filed a motion in the U.S. District Court for the District of Delaware for a preliminary injunction in its previously-disclosed patent litigation with Liquidia Technologies, Inc. ( Liquidia ) related to Liquidia's efforts to seek approval by the U.S. Food and Drug Administration ( FDA ) for a pulmonary hypertension associated with interstitial lung disease ( PH-ILD ) indication for its inhaled treprostinil product. Liquidia's investigational product is currently tentatively approved by the FDA for the treatment of pulmonary arterial hypertension ( PAH ) but not PH-ILD. In this litigation, the Company alleges that Liquidia's product for use in PH-ILD infringes the Company's U.S. Patent No. 11,826,327 (the '327 patent ), which expires in 2042. The '327 patent generally covers improving exercise capacity in patients suffering from PH-ILD by administering treprostinil by inhalation. In its preliminary injunction motion, the Company asked the district court to enjoin Liquidia from marketing its product for PH-ILD until the court can adjudicate the Company's infringement claims. Separately, as previously disclosed, the Company has initiated litigation in the U.S. District Court for the District of Columbia against the FDA in another case regarding the FDA's review of Liquidia's efforts to obtain a PH-ILD indication for its inhaled treprostinil product. Liquidia submitted an amendment to the pending new drug application ( NDA ) for its product to pursue approval for a PH-ILD indication. The suit alleges that FDA rules, precedents, and procedures require that such a new indication be pursued in a new NDA rather than as an amendment to a pending NDA. Thus, the Company has asked FDA to require Liquidia to submit a new NDA if it wishes to further pursue approval for a PH-ILD indication. The Company believes that if Liquidia is required to submit a new NDA, the Company would be ent